These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 33592561)

  • 1. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in systemic therapy for advanced biliary tract cancer.
    Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
    Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
    Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
    [No Abstract]   [Full Text] [Related]  

  • 7. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
    Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
    Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy for Biliary Tract Cancer].
    Woo SM
    Korean J Gastroenterol; 2017 Mar; 69(3):172-176. PubMed ID: 28329919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
    Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
    Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer.
    Furuse J; Okusaka T; Bridgewater J; Taketsuna M; Wasan H; Koshiji M; Valle J
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):31-9. PubMed ID: 21094052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
    Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine with carboplatin for advanced intrahepatic cholangiocarcinoma: A study from North India Cancer Centre.
    Babu VPK; Talwar V; Raina S; Goel V; Dash PK; Bajaj R; Sharma M; Medisetty P; Ram D; Agrawal C; Desiraju K; Doval DC
    Indian J Cancer; 2018; 55(3):222-225. PubMed ID: 30693882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
    Chiang NJ; Chen LT; Shan YS; Yeh CN; Chen MH
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33451059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab: A Review in Advanced Biliary Tract Cancer.
    Fung S; Syed YY
    Target Oncol; 2023 Nov; 18(6):965-972. PubMed ID: 37943483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).
    McNamara MG; Goyal L; Doherty M; Springfeld C; Cosgrove D; Sjoquist KM; Park JO; Verdaguer H; Braconi C; Ross PJ; Gramont A; Zalcberg JR; Palmer DH; Valle JW; Knox JJ
    Future Oncol; 2020 Jun; 16(16):1069-1081. PubMed ID: 32374623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
    Zheng T; Jin J; Zhou L; Zhang Y
    Oncol Res Treat; 2020; 43(9):460-469. PubMed ID: 32629449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
    Phelip JM; Desrame J; Edeline J; Barbier E; Terrebonne E; Michel P; Perrier H; Dahan L; Bourgeois V; Akouz FK; Soularue E; Ly VL; Molin Y; Lecomte T; Ghiringhelli F; Coriat R; Louafi S; Neuzillet C; Manfredi S; Malka D;
    J Clin Oncol; 2022 Jan; 40(3):262-271. PubMed ID: 34662180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine alone or in combination with Cisplatin for advanced biliary tract carcinomas: an overview of clinical evidence.
    Sun TT; Wang JL; Fang JY
    Asian Pac J Cancer Prev; 2013; 14(2):877-83. PubMed ID: 23621255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.
    Roth JA; Carlson JJ
    J Gastrointest Cancer; 2012 Jun; 43(2):215-23. PubMed ID: 21234709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.